A number of research firms have changed their ratings and price targets for Exelixis (NASDAQ: EXEL):

  • 10/2/2017 – Exelixis had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
  • 9/25/2017 – Exelixis had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 9/22/2017 – Exelixis was downgraded by analysts at Leerink Swann from an “outperform” rating to a “market perform” rating. They now have a $28.00 price target on the stock, down previously from $34.00.
  • 9/14/2017 – Exelixis is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $32.00 price target on the stock.
  • 9/12/2017 – Exelixis had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock, up previously from $28.00.
  • 9/10/2017 – Exelixis had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $29.00 price target on the stock.
  • 9/10/2017 – Exelixis had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 9/7/2017 – Exelixis had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $26.00 price target on the stock.
  • 8/25/2017 – Exelixis was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 8/14/2017 – Exelixis was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 8/10/2017 – Exelixis had its “outperform” rating reaffirmed by analysts at Cowen and Company.
  • 8/7/2017 – Exelixis was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating.

Shares of Exelixis, Inc. (NASDAQ:EXEL) traded up 0.49% during trading on Tuesday, hitting $24.40. The stock had a trading volume of 2,319,226 shares. The stock has a market cap of $7.17 billion, a price-to-earnings ratio of 123.23 and a beta of 1.92. Exelixis, Inc. has a 12-month low of $10.04 and a 12-month high of $29.50. The stock’s 50-day moving average is $26.64 and its 200-day moving average is $23.67.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.02. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The firm had revenue of $99.01 million during the quarter, compared to the consensus estimate of $85.27 million. During the same period last year, the company earned ($0.15) earnings per share. The company’s revenue for the quarter was up 173.1% on a year-over-year basis. On average, equities research analysts expect that Exelixis, Inc. will post $0.27 EPS for the current year.

In other Exelixis news, CFO Christopher J. Senner sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $26.79, for a total transaction of $2,679,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Patrick J. Haley sold 60,640 shares of the stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $27.21, for a total value of $1,650,014.40. The disclosure for this sale can be found here. Insiders sold a total of 970,152 shares of company stock valued at $25,923,457 over the last ninety days. 5.10% of the stock is currently owned by company insiders.

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Receive News & Stock Ratings for Exelixis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc and related stocks with our FREE daily email newsletter.